Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue ...

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Hims & Hers offers rare high growth at value pricing, with DCF models pointing to major upside despite volatility and short ...

Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as ...

Dave Ramsey Says "Take Social Security at 62" - Here's When That's Actually Brilliant Advice ...

HIMS & HERS HEALTH INC (HIMS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock ...